STR

Soteria Biotherapeutics is a clinical-stage biotechnology company focused on developing a novel class of T-cell engagers for the treatment of solid tumors. The company's proprietary Soteria T-cell Redirector (STR) platform utilizes a small molecule-controlled "switch" to activate bispecific antibodies specifically within the tumor microenvironment. This technology is designed to overcome the systemic toxicity and narrow therapeutic window associated with traditional T-cell redirectors, potentially allowing for higher dosing and improved efficacy. Soteria's lead program, STR-001, is currently being evaluated in clinical trials for the treatment of glypican-3 (GPC3)-positive hepatocellular carcinoma.